Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, acquiring 6.31 million B shares from Novo Holdings for DKK 4.74 ...

Novo Nordisk earned 72.8 billion kroner in operating profit over the first nine months of 2024, an 18 percent increase from last year, according to its third-quarter report. Revenue rose to nearly 205 ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).

even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance. The Danish pharmaceutical giant said that its net ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs ...

Novo Nordisk on Wednesday nudged higher its profit outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs. Novo Nordisk said its third-quarter ...